- Home
- SLNH vs SNY Comparison
SLNH vs SNY Comparison
Compare SLNH & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLNH
- SNY
- Stock Information
- Founded
- SLNH 1961
- SNY 1994
- Country
- SLNH United States
- SNY France
- Employees
- SLNH N/A
- SNY N/A
- Industry
- SLNH EDP Services
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- SLNH Technology
- SNY Health Care
- Exchange
- SLNH Nasdaq
- SNY Nasdaq
- Market Cap
- SLNH 6.9M
- SNY 123.6B
- IPO Year
- SLNH N/A
- SNY N/A
- Fundamental
- Price
- SLNH $0.89
- SNY $50.34
- Analyst Decision
- SLNH
- SNY Buy
- Analyst Count
- SLNH 0
- SNY 2
- Target Price
- SLNH N/A
- SNY $62.50
- AVG Volume (30 Days)
- SLNH 365.1K
- SNY 3.1M
- Earning Date
- SLNH 05-19-2025
- SNY 04-24-2025
- Dividend Yield
- SLNH N/A
- SNY 3.09%
- EPS Growth
- SLNH N/A
- SNY 39.56
- EPS
- SLNH N/A
- SNY 5.45
- Revenue
- SLNH $38,021,000.00
- SNY $48,817,552,946.00
- Revenue This Year
- SLNH N/A
- SNY $5.35
- Revenue Next Year
- SLNH N/A
- SNY $6.69
- P/E Ratio
- SLNH N/A
- SNY $9.56
- Revenue Growth
- SLNH 80.48
- SNY N/A
- 52 Week Low
- SLNH $0.36
- SNY $45.80
- 52 Week High
- SLNH $8.80
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- SLNH 53.38
- SNY 39.23
- Support Level
- SLNH $0.68
- SNY $51.67
- Resistance Level
- SLNH $0.95
- SNY $55.73
- Average True Range (ATR)
- SLNH 0.14
- SNY 0.88
- MACD
- SLNH 0.02
- SNY -0.09
- Stochastic Oscillator
- SLNH 60.38
- SNY 7.84
About SLNH Soluna Holdings Inc.
Soluna Holdings Inc is a U.S.-based company that conducts operations through its subsidiary. The group is engaged in the mining of cryptocurrency through data centers that can be powered by renewable energy sources. The data centers buy every excess megawatt to use for batch-oriented, computing-intensive processes such as cryptocurrency mining or machine learning which is a low-risk and low-friction solution to use as a smartphone.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.